PMV Pharmaceuticals, Inc. PMVP
1.24 USD +0.02 (+1.23%)
Nov 11, 2026, 2:08 PM EST
1.23 Day range 1.25
1.02 52-week range 1.91
- YTD
- -1.20%
- 1 year
- -7.14%
News
benzinga.com PMV Pharma Q3 EPS $(0.52) Misses $(0.34) Estimate PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.34) by 52.94 percent. This is a 30 percent decrease over losses of $(0.40)…
globenewswire.com Pivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026 Late-breaking oral presentation to highlight efficacy data across tumor types and in the ovarian cancer primary analysis population Late-breaking oral presentation to highlight efficacy data across…
benzinga.com PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push PMV Pharmaceuticals reports 46% ORR in Phase 2 trial for ovarian cancer drug rezatapopt. NDA submission planned for Q1 2027.
benzinga.com Why Pyxis Tankers Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket Shares of Pyxis Tankers Inc (NASDAQ:PXS) rose sharply in pre-market trading after the company reported better-than-expected earnings for the second quarter. The company posted quarterly earnings of…
benzinga.com PMV Pharma Q2 EPS $(0.34) Beats $(0.39) Estimate PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 17.07 percent increase over losses of $(0.41)…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com Oppenheimer Maintains Outperform on PMV Pharmaceuticals, Lowers Price Target to $5 Oppenheimer analyst Jeff Jones maintains PMV Pharmaceuticals (NASDAQ:PMVP) with a Outperform and lowers the price target from $6 to $5.
benzinga.com PMV Pharma Q1 EPS $(0.34) Beats $(0.39) Estimate PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is unchanged from the same period last year.- benzinga.com PMV Pharmaceuticals Appoints Laurie Stelzer As Board Chair, Effective June 4, Succeeding Rich Heyman PMV Pharmaceuticals, Inc. ("PMV Pharma" or the "Company"; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today…
benzinga.com PMV Pharma Q4 EPS $(0.34) Beats $(0.41) Estimate PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.41) by 16.46 percent. This is a 24.44 percent increase over losses of $(0.45)…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com PMV Pharmaceuticals Announces NEJM Publication Showing Phase 1 Rezatapopt Demonstrates Safety And Antitumor Activity In TP53 Y220C–Mutated Cancers PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today…
- benzinga.com PMV Pharma Q3 EPS $(0.40), Inline PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.40) per share which met the analyst consensus estimate. This is a 8.11 percent decrease over losses of $(0.37) per share from the same period…
benzinga.com PMV Pharmaceuticals Announces Updated Data From The Phase 2 Pivotal Portion Of The Ongoing PYNNACLE Clinical Trial In Patients With Advanced Solid Tumors Harboring A TP53 Y220C Mutation; Overall Response Rate Of 34% (35/103 Patients) Per Investigator Assessment According To Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1, Including Confirmed And Unconfirmed Responses Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning…- benzinga.com PMV Pharmaceuticals To Present Rezatapopt Pivotal Phase 2 Initial Analysis And Natural History Study Results PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer…
benzinga.com Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types PMV Pharma's Phase 2 trial shows 33% response in TP53 Y220C-mutated tumors, with ovarian cancer achieving a 43% response rate in interim results.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com PMV Pharma Announces Interim Data From Phase 2 Pivotal Portion Of PYNNACLE Clinical Trial; Plans To Submit NDA For Platinum Resistant/Refractory Ovarian Cancer By End Of Q1 2027 PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com PMV Pharma Q2 EPS $(0.41) Misses $(0.38) Estimate PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.38) by 7.05 percent. This is a 1950 percent decrease over losses of $(0.02)…
- benzinga.com PMV Pharma Q1 EPS $(0.34) Beats $(0.37) Estimate PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.37) by 8.11 percent. This is a 13.33 percent decrease over losses of $(0.30)…
- benzinga.com HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.
- benzinga.com PMV Pharma FY 2024 GAAP EPS $(1.14) Misses $(1.08) Estimate PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(1.08) by 5.56 percent.
- benzinga.com PMV Pharma Q3 EPS $(0.37) Misses $(0.35) Estimate PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.35) by 5.71 percent. This is a 8.82 percent decrease over losses of $(0.34)…
benzinga.com HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.
benzinga.com PMV Pharma Q2 EPS $(0.02) Beats $(0.33) Estimate PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.33) by 93.94 percent. This is a 94.74 percent increase over losses of $(0.38)…- benzinga.com HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.
- benzinga.com Foundation Medicine and PMV Pharma Partner to Develop Genomic Profiling for TP53 Mutation Therapy, Targets TP53 Mutation in Advanced Cancers with Investigational Therapy Rezatapopt Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ:PMVP, ", PMV Pharma", )))) today announced a partnership to develop Foundation Medicine's tissue-based comprehensive genomic profiling
- benzinga.com HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.
- benzinga.com Craig-Hallum Initiates Coverage On PMV Pharma with Buy Rating, Announces Price Target of $6 Craig-Hallum analyst Albert Lowe initiates coverage on PMV Pharma (NASDAQ:PMVP) with a Buy rating and announces Price Target of $6.
- benzinga.com PMV Pharma Q1 EPS $(0.30) Beats $(0.37) Estimate PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.37) by 18.92 percent. This is a 28.57 percent increase over losses of $(0.42)…
benzinga.com Jefferies Initiates Coverage On PMV Pharma with Buy Rating, Announces Price Target of $5 Jefferies analyst Kambiz Yazdi initiates coverage on PMV Pharma (NASDAQ:PMVP) with a Buy rating and announces Price Target of $5.- benzinga.com PMV Pharmaceuticals PYNNACLE Phase I Data Of Rezatapopt In Advanced Ovarian Cancer Featured In Oral Presentation At 2024 SGO Annual Meeting On Women's Cancer Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation…
benzinga.com HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.- benzinga.com PMV Pharmaceuticals FY23 EPS $(1.44) Vs $(1.61) YoY Fiscal Year 2023 Financial ResultsAs of December 31, 2023, PMV Pharma had $228.6 million in cash, cash equivalents, and marketable securities, compared to $243.5 million at December 31, 2022. Net…
- benzinga.com PMV Pharmaceuticals Plans Workforce Reduction Of Approximately 30%; Reveals Prioritization Of PC14586 Development And Focused Discovery Research Efforts Results Unaudited cash, cash equivalents, and marketable securities totaling approximately $229 million as of December 31, 2023, combined with cost savings from workforce reduction, is expected to extend…
- benzinga.com Ladenburg Thalmann Initiates Coverage On PMV Pharma with Buy Rating, Announces Price Target of $7 Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on PMV Pharma (NASDAQ:PMVP) with a Buy rating and announces Price Target of $7.
- benzinga.com Recap: PMV Pharma Q3 Earnings
- benzinga.com PMV Pharma Q3 EPS $(0.34) Beats $(0.45) Estimate PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.45) by 24.44 percent. This is a 15 percent increase over losses of $(0.40) per…
- benzinga.com HC Wainwright & Co. Maintains Buy on PMV Pharma, Lowers Price Target to $5 HC Wainwright & Co. analyst Robert Burns maintains PMV Pharma (NASDAQ:PMVP) with a Buy and lowers the price target from $29 to $5.
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Why Belden Shares Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Sigma Additive Solutions, Inc. (NASDAQ: SASI) shares jumped 196% to $7.34 after the company announced the signing of a definitive agreement for the acquisition of NextTrip Holdings, Inc.
- benzinga.com Precision Oncology PMV Pharmaceuticals Reveals Early Data From Cancer Study In Pretreated Patients PMV Pharmaceuticals Inc (NASDAQ: PMVP) announced updated Phase 1 results from its ongoing Phase 1/2 PYNNACLE trial that showed PC14586 achieved efficacy in heavily pretreated patients across multiple…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With A TP53 Y220C Mutation Updated PC14586 Phase 1 data presented today as a late-breaking poster at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsConfirmed responses observed in…
- benzinga.com PMV Pharmaceuticals To Present Updated Phase 1 Data On PC14586 At The 2023 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics And Host A KOL Webinar PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that it will…
- benzinga.com Why Flux Power Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enhanced backtracking search algorithm to boost the performance and efficiency of research institutions.
- benzinga.com PMV Pharmaceuticals To Present Updated Phase 1 Data On PC14586 At The 2023 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics Late-breaking poster presentation to highlight updated Phase 1 clinical data of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have…
- benzinga.com HC Wainwright & Co. Maintains Buy on PMV Pharma, Lowers Price Target to $29 HC Wainwright & Co. analyst Robert Burns maintains PMV Pharma (NASDAQ:PMVP) with a Buy and lowers the price target from $35 to $29.